Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 20-Sep-23 10:00 PM View:  | Symetryx Corp | Ohr Pharmaceutical, Inc. (NBSE) | 18-Sep-23 | Disposition (other) | -- | -- | -- | 0% 192.48K | |
| 18-Sep-23 4:32 PM View: | Symetryx Corp | Ohr Pharmaceutical, Inc. (NBSE) | 18-Sep-23 | Sale | 50,000 | $1.19 | $59,500.00 | (100%) 50.0K to 0 | |
| 18-Sep-23 4:32 PM View: | Symetryx Corp 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 15-Sep-23 | Sale | 103,337 | $1.26 | $130,205.00 | (67%) 153.34K to 50.0K | |
| 18-Sep-23 4:32 PM View: | Symetryx Corp 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 14-Sep-23 | Sale | 129,108 | $1.44 | $185,916.00 | (46%) 282.44K to 153.34K | |
| 11-Sep-23 5:08 PM View: | Symetryx Corp 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 11-Sep-23 | Sale | 3,376 | $1.44 | $4,861.44 | (< 1%) 476.3K to 472.93K | |
| 11-Sep-23 5:08 PM View: | Symetryx Corp 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 08-Sep-23 | Sale | 128,847 | $1.53 | $197,136.00 | (21%) 605.15K to 476.3K | |
| 11-Sep-23 5:08 PM View: | Symetryx Corp 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 07-Sep-23 | Sale | 74,852 | $1.80 | $134,734.00 | (11%) 680.0K to 605.15K | |
| 07-Sep-23 5:19 PM View: | Symetryx Corp 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 01-Sep-23 | Private Purchase | 61,076 | $0.98 | $59,732.30 | 10% 619.0K to 680.08K | |
| 04-Aug-23 4:39 PM View: | Stephan Dietrich A Founder and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 02-Aug-23 | Option Exercise | 93,234 | $0.02 | $2,051.15 | 68% 137.28K to 230.51K | |
| 17-Mar-23 4:11 PM View: | Branning Todd P. Chief Financial Officer | Ohr Pharmaceutical, Inc. (NBSE) | 16-Mar-23 | Grant | 54,200 | -- | -- | 181% 30.0K to 84.2K | |
| 17-Mar-23 4:11 PM View: | Stephan Dietrich A CEO and Director Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 16-Mar-23 | Grant | 153,000 | -- | -- | 6% 2.75M to 2.9M | |
| 15-Feb-23 7:30 PM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 13-Feb-23 | Option Exercise | 655,000 | -- | -- | 31% 2.09M to 2.75M | |
| 30-Sep-22 7:45 PM View: | Stephan Dietrich A CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 28-Sep-22 | Option Exercise | 750,000 | $0.00 | $825.00 | 56% 1.34M to 2.09M | |
| 01-Apr-22 4:16 PM View: | Mann William Roland Chief Operating Officer | Ohr Pharmaceutical, Inc. (NBSE) | 30-Mar-22 | Private Purchase | 6,200 | $1.92 | $11,904.00 | 124% 5.0K to 11.2K | |
| 21-Mar-22 4:06 PM View: | Branning Todd P. Chief Financial Officer | Ohr Pharmaceutical, Inc. (NBSE) | 18-Mar-22 | Private Purchase | 10,000 | $1.81 | $18,100.00 | 50% 20.0K to 30.0K | |
| 18-Mar-22 4:11 PM View: | Branning Todd P. Chief Financial Officer | Ohr Pharmaceutical, Inc. (NBSE) | 17-Mar-22 | Purchase | 10,000 | $1.74 | $17,400.00 | 100% 10.0K to 20.0K | |
| 18-Mar-22 4:11 PM View: | Branning Todd P. Chief Financial Officer | Ohr Pharmaceutical, Inc. (NBSE) | 16-Mar-22 | Private Purchase | 10,000 | $1.62 | $16,200.00 | 100% 0 to 10.0K | |
| 07-Mar-22 7:13 PM View: | Richman Eric I Director | Ohr Pharmaceutical, Inc. (NBSE) | 04-Mar-22 | Purchase | 1,000 | $1.62 | $1,620.00 | 1% 71.71K to 72.71K | |
| 07-Mar-22 7:13 PM View: | Richman Eric I Director | Ohr Pharmaceutical, Inc. (NBSE) | 03-Mar-22 | Purchase | 1,300 | $1.72 | $2,236.00 | 2% 70.41K to 71.71K | |
| 07-Mar-22 7:13 PM View: | Richman Eric I Director | Ohr Pharmaceutical, Inc. (NBSE) | 01-Mar-22 | Private Purchase | 1,580 | $1.58 | $2,496.40 | 2% 68.83K to 70.41K | |
| 05-Jan-22 9:45 PM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 31-Dec-21 | Option Exercise | 42,250 | $0.00 | $42.25 | 3% 1.3M to 1.34M | |
| 21-Jun-21 11:03 AM View: | Goldstein Dov A Md Director | Ohr Pharmaceutical, Inc. (NBSE) | 18-Jun-21 | Market Purchase | 8,000 | $4.75 | $38,000.00 | 36% 22.0K to 30.0K | (3%) |
| 27-Apr-21 4:03 PM View: | Richman Eric I Director | Ohr Pharmaceutical, Inc. (NBSE) | 26-Apr-21 | Private Purchase | 5,000 | $5.00 | $25,000.00 | 8% 63.83K to 68.83K | |
| 27-Apr-21 4:03 PM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 26-Apr-21 | Private Purchase | 12,000 | $5.00 | $60,000.00 | < 1% 1.29M to 1.3M | |
| 27-Apr-21 4:02 PM View: | Goldstein Dov A Md Director | Ohr Pharmaceutical, Inc. (NBSE) | 26-Apr-21 | Private Purchase | 12,000 | $5.00 | $60,000.00 | 120% 10.0K to 22.0K | |
| 27-Apr-21 4:01 PM View: | Mann William Roland COO | Ohr Pharmaceutical, Inc. (NBSE) | 26-Apr-21 | Private Purchase | 5,000 | $5.00 | $25,000.00 | 100% 0 to 5.0K | |
| 30-Dec-20 5:01 PM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 01-Dec-20 | Gift | 2,547,640 | -- | -- | (22%) 11.48M to 8.93M | |
| 30-Dec-20 5:01 PM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 30-Nov-20 | Gift | 1,273,820 | -- | -- | (10%) 12.75M to 11.48M | |
| 30-Dec-20 5:01 PM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 23-Nov-20 | Gift | 2,547,640 | -- | -- | (17%) 15.3M to 12.75M | |
| 10-Jun-20 11:50 AM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 09-Jun-20 | Market Purchase | 1,275 | $7.73 | $9,860.72 | < 1% 2.56M to 2.56M | (1%) |
| 26-May-20 4:39 PM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 21-May-20 | Market Purchase | 1,250 | $8.09 | $10,111.00 | < 1% 2.56M to 2.56M | (6%) |
| 04-May-20 2:18 PM View: | Goldstein Dov A Md Director | Ohr Pharmaceutical, Inc. (NBSE) | 30-Apr-20 | Private Purchase | 10,000 | $6.00 | $60,000.00 | 100% 0 to 10.0K | |
| 04-May-20 3:25 PM View: | Stephan Dietrich A President and CEO Director 10% Owner | Ohr Pharmaceutical, Inc. (NBSE) | 30-Apr-20 | Private Purchase | 10,000 | $6.00 | $60,000.00 | < 1% 2.55M to 2.56M | |
| 04-May-20 9:56 AM View: | Richman Eric I Director | Ohr Pharmaceutical, Inc. (NBSE) | 30-Apr-20 | Private Purchase | 2,500 | $6.00 | $15,000.00 | 5% 52.99K to 55.49K | |
| 04-May-20 12:28 PM View: | Backenroth Samuel CFO, Treasurer & Secretary | Ohr Pharmaceutical, Inc. (NBSE) | 30-Apr-20 | Private Purchase | 1,000 | $6.00 | $6,000.00 | 9% 10.63K to 11.63K | |
| 04-May-20 9:56 AM View: | Richman Eric I Director | Ohr Pharmaceutical, Inc. (NBSE) | 30-Apr-20 | Private Purchase | 8,333 | $6.00 | $49,998.00 | 15% 55.49K to 63.83K | |
| 16-Jul-19 8:35 PM View: | Richman Eric I Director | Ohr Pharmaceutical, Inc. (NBSE) | 12-Jul-19 | Grant | 25,247 | -- | -- | 100% 0 to 25.25K | |
| 16-Jul-19 8:35 PM View: | Stephan Dietrich A President and CEO Director | Ohr Pharmaceutical, Inc. (NBSE) | 12-Jul-19 | Grant | 2,547,640 | -- | -- | 100% 0 to 2.55M | |
| 13-Apr-17 2:45 PM View: | Slakter Jason Scott Chief Executive Officer Director | Ohr Pharmaceutical, Inc. (NBSE) | 10-Apr-17 | Market Purchase | 142,858 | $0.70 | $100,001.00 | 7% 2.12M to 2.26M | (61%) |
| 13-Apr-17 11:11 AM View: | Hirschman Orin Director | Ohr Pharmaceutical, Inc. (NBSE) | 10-Apr-17 | Market Purchase Duplicate | 142,858 | $0.70 | $100,001.00 | 9% 1.64M to 1.79M | (61%) |
| 13-Apr-17 12:59 PM View: | Backenroth Samuel Chief Financial Officer | Ohr Pharmaceutical, Inc. (NBSE) | 10-Apr-17 | Market Purchase | 71,429 | $0.70 | $50,000.30 | 51% 141.17K to 212.6K | (61%) |
| 02-Aug-16 12:15 PM View: | Slakter Jason Scott Chief Executive Officer Director | Ohr Pharmaceutical, Inc. (NBSE) | 18-Jul-16 | Acquisition (other) | 497,859 | -- | -- | 31% 1.62M to 2.12M | |
| 21-Jun-16 12:41 PM View: | Backenroth Samuel Chief Financial Officer | Ohr Pharmaceutical, Inc. (NBSE) | 20-Jun-16 | Market Purchase | 2,468 | $2.84 | $6,997.44 | 2% 138.7K to 141.17K | (90%) |
| 21-Jun-16 12:48 PM View: | Slakter Jason Scott Chief Executive Officer Director | Ohr Pharmaceutical, Inc. (NBSE) | 20-Jun-16 | Market Purchase | 8,786 | $2.85 | $24,999.70 | < 1% 1.61M to 1.62M | (90%) |
| 26-May-16 12:08 PM View: | Slakter Jason Scott Chief Executive Officer Director | Ohr Pharmaceutical, Inc. (NBSE) | 25-May-16 | Market Purchase | 3,682 | $3.11 | $11,446.60 | < 1% 1.61M to 1.61M | (91%) |
| 25-May-16 1:25 PM View: | Slakter Jason Scott Chief Executive Officer Director | Ohr Pharmaceutical, Inc. (NBSE) | 24-May-16 | Market Purchase | 7,503 | $3.09 | $23,177.70 | < 1% 1.6M to 1.61M | (91%) |
| 25-May-16 1:25 PM View: | Slakter Jason Scott Chief Executive Officer Director | Ohr Pharmaceutical, Inc. (NBSE) | 23-May-16 | Market Purchase | 20,565 | $3.17 | $65,199.30 | 1% 1.58M to 1.6M | (91%) |
| 24-May-16 12:39 PM View: | Backenroth Samuel Chief Financial Officer | Ohr Pharmaceutical, Inc. (NBSE) | 23-May-16 | Market Purchase | 2,500 | $3.17 | $7,926.00 | 2% 136.2K to 138.7K | (91%) |
| 12-Apr-16 1:02 PM View: | Slakter Jason Scott Chief Executive Officer Director | Ohr Pharmaceutical, Inc. (NBSE) | 11-Apr-16 | Market Purchase | 6,250 | $3.35 | $20,937.50 | < 1% 1.58M to 1.58M | (92%) |
| 09-Mar-16 1:17 PM View: | Slakter Jason Scott Chief Executive Officer Director | Ohr Pharmaceutical, Inc. (NBSE) | 07-Mar-16 | Market Purchase | 6,250 | $3.63 | $22,668.90 | < 1% 1.57M to 1.58M | (92%) |
